AstraZeneca has signed a drug discovery collaboration and licensing agreement with insitro to apply artificial intelligence ...
President Trump’s Most-Favored Nation (MFN) initiative continues to impact the industry. Most recently, the deadline passed ...
Pharmaceutical Executive spoke with Marc Wagner, an FDA and life sciences attorney at Fox Rothschild, about the manufacturing ...
Why “we’re safe” is the most dangerous assumption in medical benefit commercialization. There is a conversation happening in boardrooms and brand planning cycles across the pharmaceutical industry ...
After months of prodding, the European Medicines Agency (EMA) and member states of the European Union have begun taking ...
Roche licenses Rona Therapeutics’ ALK7-targeting RNAi candidate for obesity, while Pfizer partners with Enodia Therapeutics ...
Fox Rothschild's Mark Wagner on why scaling drug production is so slow — overseas API sourcing, supplier qualification, and ...
The FDA approved Enspryng (satralizumab) on Oct. 16 for adults with thyroid eye disease (TED). 1 Roche describes the ...
Drug shortages remain a difficult to fix issue for the pharma industry and are an issue that can have devastating results.
Thomas Appio has been named interim CEO of Bausch + Lomb, a move coinciding with an expected upward revision to the company’s ...
MERGE's Pat McGloin on why pharma AI fails when strategy follows technology — and why the brilliant basics still have to come ...
In today’s Pharmaceutical Executive Daily, Gilead and Vir Biotechnology enter a collaboration worth up to $1.87 billion to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results